Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Immunodominant Announces Call for Initial Investment Round for Phase 2 Study of Of OTC COVID-19 DrugBy: Immunodominant Inc Immunodominant also announced today that it is scheduling a Phase 2 clinical study after a pre-IND meeting with the FDA for LACTOVID, a novel, oral, over-the-counter drug for the prevention and treatment of adults with COVID-19, including long COVID. LACTOVID is designed to be taken as one OTC product combining two compounds with direct antiviral activity against COVID-19 (through multiple mechanisms of action including binding to sigma receptors, binding to ACE2, blocking viral entry by neutralizing heparan sulphates, and by regulating inflammatory responses). Antiviral activity of LACTOVID has been observed in vitro (99% inhibition of SARS-CoV-2 replication) "We are now at a point where we are seeking strategic partners that share our vision of combatting emerging threats and improving human health. We are enthusiastic to take this next step," said David Ostrov, PhD, Immunodominant's Founder and CEO; and member of the Global Virus Network's COVID-19 Taskforce. "LACTOVID will be more accessible as an OTC product as the safety profile of its two well-known compounds have fewer side-effects and dangerous drug interactions compared to newer drugs." "We anticipate a successful Phase 2 study for our IND application," "There is a large gap in the market for an OTC product for COVID," said Marcus Kirk, PhD, Immunodominant's CFO. "We are aiming to be broadly available in the U.S. and international markets as an OTC product with fewer drug interactions, and for both the prevention and treatment of COVID, including long COVID symptoms." "We are delighted to reach a stage exploring a strategic collaboration and investment," http://www.immunodominant.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|